 SOUTH SAN FRANCISCO, Calif., July 25, 2021 GLOBE NEWSWIRE -- Denali Therapeutics Inc. NASDAQ: DNLI, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier BBB for neurodegenerative diseases, today announced additional positive interim data from a Phase 12 study evaluating ETV:IDS DNL310, an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system CNS and peripheral manifestations of Hunter syndrome MPS II. The interim results being presented today at MPS 2021, the 16th International Symposium on MPS and Related Diseases, include safety data up to Weeks 43 and 25 from Cohorts A and B, respectively, 6-month biomarker data from Cohort A and up to 3-month biomarker data from Cohort B. Denali Management will host a webinar today for analysts and investors beginning at approximately 11:30 a.m. Eastern Time. 